Enovis (NYSE:ENOV) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Enovis (NYSE:ENOV) from a buy rating to a hold rating in a report published on Saturday,Wall Street Zen reports.

A number of other equities analysts have also commented on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Enovis in a research report on Wednesday, September 2nd. BMO Capital Markets set a $27.00 price objective on shares of Enovis in a research note on Tuesday, September 1st. Canaccord Genuity Group cut their price objective on shares of Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a report on Monday, August 17th. Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Finally, BTIG Research decreased their target price on shares of Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday, September 1st. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Enovis presently has an average rating of “Moderate Buy” and an average target price of $37.25.

Enovis Stock Performance

Shares of NYSE ENOV opened at $18.25 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -0.95 and a beta of 1.37. The stock’s fifty day moving average price is $21.48 and its two-hundred day moving average price is $23.27. Enovis has a one year low of $16.70 and a one year high of $34.28.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. The company had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The company’s revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts forecast that Enovis will post 3.15 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Damien Mcdonald acquired 13,035 shares of the stock in a transaction on Friday, September 4th. The shares were purchased at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the purchase, the chief executive officer directly owned 247,077 shares in the company, valued at approximately $4,731,524.55. The trade was a 5.57% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Oliver Engert acquired 5,140 shares of the company’s stock in a transaction on Thursday, September 3rd. The stock was bought at an average cost of $19.46 per share, with a total value of $100,024.40. Following the completion of the acquisition, the insider directly owned 61,238 shares in the company, valued at approximately $1,191,691.48. This represents a 9.16% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 23,293 shares of company stock worth $449,599. Corporate insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. IFP Advisors Inc raised its holdings in shares of Enovis by 5,590.5% during the 2nd quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after buying an additional 1,174 shares in the last quarter. Allworth Financial LP acquired a new stake in Enovis in the second quarter valued at about $36,000. Integrated Wealth Concepts LLC acquired a new stake in Enovis in the second quarter valued at about $39,000. Public Employees Retirement System of Ohio bought a new position in Enovis in the second quarter valued at about $48,000. Finally, Annis Gardner Whiting Capital Advisors LLC grew its position in Enovis by 468,400.0% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 4,685 shares of the company’s stock valued at $107,000 after acquiring an additional 4,684 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient outcomes and support the restoration of movement. Its portfolio serves orthopedic, rehabilitation and recovery markets, with products used by physicians, hospitals, physical therapists, athletic trainers and consumers.

The company’s offerings include orthopedic braces and supports, cold and compression therapy systems, rehabilitation equipment, electrical stimulation and ultrasound products, surgical implants and related technologies.